Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.

Cell host & microbe - 13 Jan 2021

Martinez David R, Metz Stefan W, Baric Ralph S

Abstract excerpt

More than 390 million human dengue virus (DENV) infections occur each year, worldwide. Dengvaxia, a live-virus tetravalent vaccine from Sanofi Pasteur, was recently approved for human clinical use, although vaccine performance against the four DENV serotypes is highly variable. Other dengue vaccines in advanced clinical testing also demonstrate variability in efficacy. In this review, we outline the benefits and...

Topics

Join the communities discussing this publication.

Antibodies, Neutralizing
Dengue
Dengue Virus
Immunogenicity, Vaccine
Vaccines, Attenuated

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Vaccines, Inactivated

Vaccines, Subunit

Vaccines, Synthetic

Source

Identifiers

PMID: 33444553
DOI: 10.1016/j.chom.2020.12.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.PMID 33444553Read ↗

Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against DengueSemantic proximity Read ↗

Human T Cell Response to Dengue Virus InfectionSemantic proximity Read ↗

CD4+ T Cell Help Shapes Protective Humoral Immunity in Primary Dengue 2 Virus Infection: Implications for Rational Vaccine DesignSemantic proximity Read ↗

The Human CD8 <sup>+</sup> T Cell Responses Induced by a Live Attenuated Tetravalent Dengue Vaccine Are Directed against Highly Conserved EpitopesSemantic proximity Read ↗

The relevance of dengue virus genotypes surveillance at country level before vaccine approval.Semantic proximity Read ↗

Preexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human ChallengeSemantic proximity Read ↗

Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimensSemantic proximity Read ↗

Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domainsSemantic proximity Read ↗

A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infectionSemantic proximity Read ↗

Dengue: A Minireview.Semantic proximity Read ↗

Stabilized dengue virus 2 envelope subunit vaccine redirects the neutralizing antibody response to all E-domainsSemantic proximity Read ↗

Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.